Why during a pandemic is the FDA not looking for something that works and designing trials that lead to proper dose, proper timing, proper administration of the dose?

Instead this seems to be up to the drug company and then for the FDA sit back and give a review on all the negative aspects.

I mean with Leronlimab shouldn't have been, "It seems to work up to here, but after 14 days it dropped off, should we try a bunch of patients with extended doses or higher doses?" Let's work on this "together" and see if we can get better results.